Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03925480
Other study ID # HREC 38057
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 1, 2019
Est. completion date February 28, 2023

Study information

Verified date April 2023
Source Murdoch Childrens Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A trial to assess cumulative incidence of skin and soft tissue infections (SSTI) in infants (by three months of age) born to mothers receiving a single-dose of 2 grams of oral azithromycin during labour (or immediately prior to delivery in the case of caesarean section), compared to infants whose mothers received placebo.


Description:

PreYIAL is a Phase III, double-blind, randomised, placebo controlled two arm trial of a single 2g dose of azithromycin or placebo, administered to women who have been admitted for delivery of their baby (either following onset of labour or for caesarean section). The trial includes an estimated 2110 mothers/infant pairs (1055 per arm), with 12 months of follow-up for the mother/infant pair. A swab-study within the main study involves 940 of the mother/infant pairs enrolled and involves follow-up for bacterial carriage outcomes, for 12 months.These swab-study participants will also be included in assessments of the infant and maternal microbiome.


Recruitment information / eligibility

Status Completed
Enrollment 2110
Est. completion date February 28, 2023
Est. primary completion date May 25, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion criteria: 1. Pregnant women at least 18 years old intending to deliver at Colonial War Memorial Hospital (CWMH) 2. Women who have been admitted to CWMH for delivery at the time of eligibility assessment 3. Women who expect to be available, with their infant, for the duration of the study, and who agree to adhere to all protocol requirements 4. Women who will have a main place of residence within the Greater Suva area for the follow-up period and within a practical distance of the study site to allow compliance with protocol-required visits and follow-up, including attending follow-up at specified clinics 5. Women who have provided written informed consent prior to study-related procedures being performed Exclusion criteria: 1. Women who have a known macrolide allergy 2. Women who have taken antibiotics in the week prior to randomisation 3. A women who is unable or unwilling to provide informed consent for her participation in the trial or the participation of her infant 4. Women who decide prior to randomisation that they are no longer willing to participate or to have their infant participate 5. Women who have ever received, or who are anticipated to receive during the study period, any investigational agent other than the study drug 6. Women who are CWMH, Murdoch Children's Research Institute (MCRI) or study site employees who work directly with study staff, or who are working on the study 7. Women taking warfarin due to the potential for drug interactions with azithromycin 8. Women with any cardiac abnormality 9. Women taking other medications known to prolong the QT interval such as antiarrhythmics; antipsychotic agents; antidepressants; and fluoroquinolones; 10. Women with known electrolyte disturbances: including in cases of hypokalaemia and hypomagnesaemia 11. Women who will undergo general anaesthetic for delivery 12. Women carrying a foetus with intrauterine death confirmed before randomisation 13. Women carrying a foetus with a prognosis unlikely to survive 14. Women with known HIV infection and/or taking nelfinavir 15. Women who have participated in the study during a previous pregnancy 16. Women who have been admitted for management of premature labour who have unruptured membranes (This is a temporary exclusion such that the participant may be assessed for eligibility again in the same or a subsequent admission to CWMH). 17. Women with renal impairment 18. Women with hepatic impairment 19. Women with myasthenia gravis 20. Women who are taking any ergot medications

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azithromycin 500 mg Oral Tablet x 4
A single prophylactic dose of antibiotic given during labour
Matching Placebo
Matching Placebo

Locations

Country Name City State
Fiji Colonial War Memorial Hospital and Mother and Child Health Clinics Suva Central

Sponsors (2)

Lead Sponsor Collaborator
Murdoch Childrens Research Institute Ministry of Health, Fiji

Country where clinical trial is conducted

Fiji, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence of skin and soft tissue infection by 3 months of age in infants Born to mothers receiving a single dose of 2g Azithromycin during labour. Assessed by history and physical examination at 7 days, 6 weeks and 3 months. 3 months
Secondary Cumulative incidence of skin and soft tissue infection, and other infections by 12 months of age in infants To compare intervention and placebo groups with regard to the cumulative incidence of infant infection (meningitis, sepsis, pneumonia, SSTI, fever, diarrhoea, urinary tract infection) up to 12 months of age; Birth to 12 Months
Secondary Cumulative incidence of maternal infection by 6 weeks and 12 months post-delivery To compare intervention and placebo groups with regard to the cumulative incidence of maternal infection (mastitis, sepsis, post-operative wound infections, SSTI, fever, meningitis, pneumonia, abdominal or pelvic abscess, endometritis, urinary tract infection, pyelonephritis) by six weeks post-delivery, and similarly up to 12 months post-delivery Delivery to 12 months
Secondary Cumulative incidence of antibiotic usage by 12 months in infants To compare intervention and placebo groups with regard to the cumulative incidence of the number of courses of antibiotics prescribed to the infant up to 12 months of age; Birth to 12 months
Secondary Cumulative incidence of maternal antibiotic usage by 12 months post-delivery To compare intervention and placebo groups with regard to the cumulative incidence of the number of courses of antibiotics prescribed to the mother up to 12 months post-delivery Delivery to 12 months
Secondary Number of infant participants with adverse events as assessed by adapted version of CTCAE v5.0 and DAID v2.1 To compare the number of adverse events including solicited non serious adverse events and all serious adverse events as per study specific definitions throughout the duration of the study. Birth to 12 months
Secondary Number of maternal participants with adverse events as assessed by adapted version of CTCAE v5.0 and DAID v2.1 To compare the number of adverse events including solicited non serious adverse events and all serious adverse events as per study specific definitions throughout the duration of the study. Delivery to 12 months
Secondary Number of infant and maternal participants with Staphylococcus aureus and/or Group A streptococcus as assessed by real-time quantitative PCR (qPCR) from impetigo swabs The proportion of participants that have Staphylococcus aureus and/or Group A streptoccoccus detected by qPCR from impetigo swabs at key time points throughout the duration of the study, between the two groups Delivery/birth to 12 months
Secondary Number of infant and maternal participants with Staphylococcus aureus and/or Group A streptococcus with azithromycin nonsusceptibility cultured from impetigo swabs. The proportion of participants that have Staphylococcus aureus and/or Group A streptococcus that is non susceptible to azithromycin cultured from impetigo swabs at key time points throughout the duration of the study, between the two groups Delivery/birth to 12 months
Secondary Swab study outcome - Prevalence of bacterial carriage as assessed by real-time quantitative PCR (qPCR) Bacterial carriage, the proportion of participants that have at least one of the following bacterial species including GBS, SA, SPN, GAS or E. coli, assessed by qPCR at key time points throughout the duration of the study, between the two groups Delivery/birth to 12 months
Secondary Swab study outcome - Density of bacterial carriage as assessed by real-time quantitative PCR (qPCR) Density of bacterial carriage, reported as log 10 genome equivalents/ml, of the participants that have at least one of the following bacterial species including GBS, SA, SPN, GAS or E. coli, assessed by qPCR at key time points throughout the duration of the study, between the two groups Delivery/birth to 12 months
Secondary Swab study outcome - Risk of maternal carriage identified through qPCR of common organisms relevant to Sexually Transmitted Infections (STI) Maternal carriage of common organisms relevant to Sexually Transmitted Infections (STI) (including Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, HSV-1 and HSV-2) as detected by qPCR at key time points throughout the duration of the study, between the two groups. Delivery/birth to 6 months
Secondary Swab study outcome - Risk of antibiotic nonsusceptibility in culture isolates Antibiotic non susceptibility, based on the proportion of samples from mothers and infants that are non susceptible to antibiotics cultured in the two arms, at key time points throughout the duration of the study Delivery/birth to 12 months
Secondary Swab study outcome - The prevalence of infants with diagnoses that have been associated with microbiome dysbiosis To compare the infant and maternal microbiome of specified body sites at key time points in the intervention and placebo groups Delivery/birth to 6 months
See also
  Status Clinical Trial Phase
Completed NCT03726216 - Xydalba Utilization Registry in France
Completed NCT03605498 - OR PathTrac (Tracking Intra-operative Bacterial Transmission)
Withdrawn NCT05269121 - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections Phase 1/Phase 2
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Recruiting NCT02074865 - Children's Antibiotic Resistant Infections in Low Income Countries N/A
Completed NCT01689207 - To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) Phase 1
Completed NCT01932034 - Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software N/A
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Not yet recruiting NCT01159470 - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children N/A
Completed NCT00983255 - Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) Phase 1
Completed NCT00678106 - Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections Phase 1
Completed NCT00799591 - French Study In ICU Patients Treated With Tigecycline N/A
Completed NCT00478855 - Tazocin Intervention Study Phase 4
Completed NCT01074775 - Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection N/A
Terminated NCT00431028 - Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery Phase 1/Phase 2
Not yet recruiting NCT03634904 - Serum Ceftazidime Concentrations in Hemodialysis Patients N/A
Recruiting NCT05684705 - Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 Phase 1
Recruiting NCT03858387 - PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Enrolling by invitation NCT04764058 - Efficacy and Safety of Colistin Based Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2